Find Funding Opportunities

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA or ACF awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2012-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, FDA and ACF

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2012-2 SBIR/STTR Program Descriptions and Research Topics for NIH.)

The purpose of this FOA is to encourage applications for the Leadership Group for a Clinical Research Network on Therapeutics for HIV/AIDS and HIV-associated Infections in Adults. The Leadership Group (LG) will have overall responsibility for developing, implementing and adapting the networks clinical research agenda to address NIAIDs HIV/AIDS scientific priorities described below (Part 2, Section I, #3). Applications for the LG must be comprised of three separate linked UM1 applications: a Leadership and Operations Center (LOC), a Laboratory Center (LC) and a Statistical and Data Management Center (SDMC).

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health, encourages applications that will develop novel technologies and/or tools to facilitate the study of genes and proteins at the synapse on a large scale. Being able to characterize the synaptome in the context of hundreds of genes/proteins would be a major advance for basic and translational research. The technologies/tools created would be expected to affect the fields of neurology, psychiatry, and neuroscience by enriching existing resources as well as those in development. The new tools should enable discovery science related to the synapse by providing for substantially greater sensitivity, selectivity, spatiotemporal resolution and markedly decreased costs compared to currently available technologies.

The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences supports broad and fundamental research training in the neurosciences via institutional NRSA research training grants (T32) at domestic institutions of higher education. Trainees appointed to this training grant are financially supported for either one or two years, during the first 2 years of their graduate research training. The primary objective is to prepare individuals for careers in neuroscience that have a significant impact on the health-related research needs of the Nation.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy (CIPN). The majority of acquired peripheral neuropathy research has focused on diabetic and inherited diseases; this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevention CIPN.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy (CIPN). The majority of acquired peripheral neuropathy research has focused on diabetic and inherited diseases; this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevention CIPN.

NINDS invites new and competing renewal applications for Center Core Grants that provide resources and facilities shared by a minimum of six NINDS-supported investigators. The proposed Centers will offer services and expertise that would be difficult or impractical to support in individual labs. The Centers are expected to capitalize on economies and synergies associated with shared resources, and to foster a collaborative environment among neuroscientists at host institutions.

The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Technology Transfer (STTR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics as well as surgical, behavioral or rehabilitation therapies. Only Phase II and Fast-Track applications are supported under this program. Phase I applications are only accepted as part of a Fast-track application.

The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics as well as surgical, behavioral or rehabilitation therapies. Only Phase II and Fast-Track applications are supported under this program. Phase I applications are only accepted as part of a Fast-track application.